切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2025, Vol. 14 ›› Issue (05) : 659 -666. doi: 10.3877/cma.j.issn.2095-3232.2025.05.001

述评

肝癌合并门静脉癌栓放射治疗
袁洳靖, 孙居仙, 程树群†()   
  1. 200438　上海，海军军医大学第三附属医院（上海东方肝胆外科医院）肝外六科
  • 收稿日期:2025-04-25 出版日期:2025-10-10
  • 通信作者: 程树群
  • 基金资助:
    国家自然科学基金面上项目(82073293); 海军军医大学面上孵育项目(2022MS038); 海军军医大学第三附属医院腾飞工程人才项目(TF2024YSBJ09)

Radiotherapy for liver cancer complicated with portal vein tumor thrombus

Rujing Yuan, Juxian Sun, Shuqun Cheng†()   

  1. Department Ⅵ of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, the Third Affiliated Hospital of Naval Medical University, Shanghai 200438, China
  • Received:2025-04-25 Published:2025-10-10
  • Corresponding author: Shuqun Cheng
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

袁洳靖, 孙居仙, 程树群. 肝癌合并门静脉癌栓放射治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(05): 659-666.

Rujing Yuan, Juxian Sun, Shuqun Cheng. Radiotherapy for liver cancer complicated with portal vein tumor thrombus[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(05): 659-666.

门静脉癌栓（PVTT）发生率高，预后差，是肝癌整体疗效提高的瓶颈。PVTT现有的治疗手段包括手术、放疗、肝动脉栓塞化疗以及系统治疗等，其中放疗是近年来发展最快的领域之一。新的放疗技术如三维适形放疗（3DCRT）、调强放疗（IMRT）、立体定向放疗（SBRT）和质子重离子治疗（PBT）等可显著提升治疗效果并保护正常肝组织，可贯穿在肝癌合并PVTT的整个治疗过程中，为联合其他治疗手段进一步提高PVTT疗效起到了重要作用。本文对放疗在肝癌合并PVTT治疗中的应用进展做一探讨。

关键词: 癌，肝细胞, 门静脉癌栓, 放射治疗

The incidence of portal vein tumor thrombus (PVTT) is high with poor prognosis. It is the bottleneck to improve the overall efficacy of liver cancer. The existing treatment methods for PVTT include surgery, radiotherapy, transcatheter arterial chemoembolization and systemic therapy, among which radiotherapy is one of the fastest-growing fields in recent years. New radiotherapy techniques, such as three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT) and proton beam therapy (PBT), can significantly increase the therapeutic dose and protect normal liver tissues, which can proceed throughout the whole treatment process of liver cancer complicated with PVTT, and play a critical role in further enhancing treatment efficacy of PVTT when combining with alternative treatments. In this article, recent progress in radiotherapy for liver cancer complicated with PVTT was reviewed.

Key words: Carcinoma, hepatocellular, Portal vein tumor thrombus, Radiotherapy
[1]
Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022[J]. Zhonghua Zhong Liu Za Zhi, 2024, 46(3): 221-231. DOI: 10.3760/cma.j.cn112152-20240119-00035.
[2]
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49. DOI: 10.3322/caac.21820.
[3]
Sun J, Guo R, Bi X, et al. Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2021 edition)[J]. Liver Cancer, 2022, 11(4): 315-328. DOI: 10.1159/000523997.
[4]
Schöniger-Hekele M, Müller C, Kutilek M, et al. Hepatocellular carcinoma in central Europe: prognostic features and survival[J]. Gut, 2001, 48(1): 103-109. DOI: 10.1136/gut.48.1.103.
[5]
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update[J]. J Hepatol, 2022, 76(3): 681-693. DOI: 10.1016/j.jhep.2021.11.018.
[6]
中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(4): 407-449. DOI: 10.3877/cma.j.issn.2095-3232.2024.04.001.
[7]
Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol, 2019, 37(24): 2141-2151. DOI: 10.1200/JCO.18.02184.
[8]
Song X, He Y, Liang H, et al. INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus[J]. BMC Surg, 2020, 20(1): 174. DOI: 10.1186/s12893-020-00836-2.
[9]
Wang L, Liu Y, Rong W, et al. The role of intraoperative electron radiotherapy in centrally located hepatocellular carcinomas treated with narrow-margin (<1 cm) hepatectomy: a prospective, phase 2 study[J]. Hepatobiliary Surg Nutr, 2022, 11(4): 515-529. DOI: 10.21037/hbsn-21-223.
[10]
Sun J, Yang L, Shi J, et al. Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: an open-label randomized controlled trial[J]. Radiother Oncol, 2019, 140: 20-25. DOI: 10.1016/j.radonc.2019.05.006.
[11]
Kishi N, Kanayama N, Hirata T, et al. Preoperative stereotactic body radiotherapy to portal vein tumour thrombus in hepatocellular carcinoma: clinical and pathological analysis[J]. Sci Rep, 2020, 10(1): 4105. DOI: 10.1038/s41598-020-60871-0.
[12]
Bai S, Wu Y, Yan Y, et al. Evaluation of the efficacy and toxicity of radiotherapy for type Ⅲ-Ⅳ portal vein tumor thrombi[J]. Technol Cancer Res Treat, 2021, 20: 1533033821995286. DOI: 10.1177/1533033821995286.
[13]
Hamaoka M, Kobayashi T, Kuroda S, et al. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: a retrospective cohort study[J]. Int J Surg, 2017, 44: 223-228. DOI: 10.1016/j.ijsu.2017.06.082.
[14]
Kim J, Cheng JC, Nam TK, et al. Efficacy of liver-directed combined radiotherapy in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancers, 2023, 15(12): 3164. DOI: 10.3390/cancers15123164.
[15]
Xiao Y, Li K, Zhao Y, et al. Efficacy of radiotherapy in combined treatment of hepatocellular carcinoma patients with portal vein tumor thrombus: a real-world study[J]. BMC Surg, 2024, 24(1): 54. DOI: 10.1186/s12893-024-02334-1.
[16]
Dutta D, Yarlagadda S, Kalavagunta S, et al. Co-relation of portal vein tumour thrombus response with survival function following robotic radiosurgery in vascular invasive hepatocellular carcinoma[J]. J Clin Exp Hepatol, 2024, 14(5): 101404. DOI: 10.1016/j.jceh.2024.101404.
[17]
Sharma D, Thaper D, Kamal R, et al. Role of palliative SBRT in Barcelona clinic liver cancer-stage C hepatocellular carcinoma patients[J]. Strahlenther Onkol, 2023, 199(9): 838-846. DOI: 10.1007/s00066-023-02065-x.
[18]
Zhang S, He L, Bo C, et al. Comparison of stereotactic body radiation therapy versus fractionated radiation therapy for primary liver cancer with portal vein tumor thrombus[J]. Radiat Oncol, 2021, 16(1): 149. DOI: 10.1186/s13014-021-01874-7.
[19]
Li LQ, Zhou Y, Huang Y, et al. Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis[J]. Hepatol Int, 2021, 15(3): 630-641. DOI: 10.1007/s12072-021-10173-y.
[20]
Ishida T, Mizumoto M, Saito T, et al. Proton beam therapy for treating patients with hepatocellular carcinoma with major portal vein tumor invasion: a single center retrospective study[J]. Cancers, 2024, 16(11): 2050. DOI: 10.3390/cancers16112050.
[21]
Kaneko T, Makishima H, Wakatsuki M, et al. Carbon-ion radiotherapy for hepatocellular carcinoma with major vascular invasion: a retrospective cohort study[J]. BMC Cancer, 2024, 24(1): 383. DOI: 10.1186/s12885-024-12154-4.
[22]
Sidhu MS, Ramandeep, Sood S, et al. Role of rapid arc-image-guided radiotherapy in hepatocellular carcinoma with portal vein tumor thrombosis: a study from tertiary care center in Punjab, India[J]. J Cancer Res Ther, 2023, 19(3): 639-643. DOI: 10.4103/jcrt.jcrt_365_21.
[23]
Fang F, Qiu B, Zhen P, et al. Hypofractionated radiotherapy for palliation of main portal vein tumor thrombosis[J]. Front Oncol, 2022, 12: 882272. DOI: 10.3389/fonc.2022.882272.
[24]
Lee SJ, Kim M, Kwak YK, et al. MRI-guided radiotherapy for PVTT in HCC patients: evaluation of the efficacy and safety[J]. J Cancer Res Clin Oncol, 2022, 148(9): 2405-2414. DOI: 10.1007/s00432-021-03788-z.
[25]
Su K, Gu T, Xu K, et al. Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study[J]. Hepatol Int, 2022, 16(4): 858-867. DOI: 10.1007/s12072-022-10339-2.
[26]
Asagi A, Sakaguchi C, Nadano S, et al. Efficacy and safety of three-dimensional conformal radiotherapy for macroscopic vascular invasion of hepatocellular carcinoma[J]. Acta Med Okayama, 2022, 76(6): 679-688. DOI: 10.18926/AMO/64118.
[27]
Khorprasert C, Thonglert K, Alisanant P, et al. Advanced radiotherapy technique in hepatocellular carcinoma with portal vein thrombosis: feasibility and clinical outcomes[J]. PLoS One, 2021, 16(9): e0257556. DOI: 10.1371/journal.pone.0257556.
[28]
Yoon SM, Ryoo BY, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial[J]. JAMA Oncol, 2018, 4(5): 661-669. DOI: 10.1001/jamaoncol.2017.5847.
[29]
Lee SK, Kwon JH, Lee SW, et al. A real-world comparative analysis of atezolizumab plus bevacizumab and transarterial chemoembolization plus radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombosis[J]. Cancers, 2023, 15(17): 4423. DOI: 10.3390/cancers15174423.
[30]
Zhang XF, Lai L, Zhou H, et al. Stereotactic body radiotherapy plus transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma patients with portal vein tumour thrombus: a meta-analysis[J]. PLoS One, 2022, 17(5): e0268779. DOI: 10.1371/journal.pone.0268779.
[31]
Chu HH, Kim JH, Shim JH, et al. Chemoembolization plus radiotherapy versus chemoembolization plus sorafenib for the treatment of hepatocellular carcinoma invading the portal vein: a propensity score matching analysis[J]. Cancers, 2020, 12(5): 1116. DOI: 10.3390/cancers12051116.
[32]
Guo L, Wei X, Feng S, et al. Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial[J]. Hepatol Int, 2022, 16(6): 1368-1378. DOI: 10.1007/s12072-022-10423-7.
[33]
Ji X, Xu Z, Sun J, et al. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study[J]. Radiat Oncol, 2023, 18(1): 101. DOI: 10.1186/s13014-023-02270-z.
[34]
Cheng JY, Huang BS, Chen YY, et al. Combination of lenvatinib and proton beam therapy in the management of patients with advanced hepatocellular carcinoma[J]. Anticancer Res, 2023, 43(3): 1361-1371. DOI: 10.21873/anticanres.16284.
[35]
Yu JI, Kang W, Yoo GS, et al. Safety and efficacy of liver-directed radiotherapy in combination with lenvatinib for hepatocelluar carcinoma with macroscopic tumor thrombosis[J]. Front Oncol, 2022, 12: 888755. DOI: 10.3389/fonc.2022.888755.
[36]
Abulimiti M, Li Z, Wang H, et al. Combination intensity-modulated radiotherapy and sorafenib improves outcomes in hepatocellular carcinoma with portal vein tumor thrombosis[J]. J Oncol, 2021, 2021: 9943683. DOI: 10.1155/2021/9943683.
[37]
Zhu M, Liu Z, Chen S, et al. Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a multicenter, single-arm, phase 2 study[J]. Hepatology, 2024, 80(4): 807-815. DOI: 10.1097/HEP.0000000000000776.
[38]
Su CW, Teng W, Shen EY, et al. Concurrent atezolizumab plus bevacizumab and high-dose external beam radiotherapy for highly advanced hepatocellular carcinoma[J]. Oncologist, 2024, 29(7): e922-e931. DOI: 10.1093/oncolo/oyae048.
[39]
Hu Y, Zhou M, Tang J, et al. Efficacy and safety of stereotactic body radiotherapy combined with camrelizumab and apatinib in patients with hepatocellular carcinoma with portal vein tumor thrombus[J]. Clin Cancer Res, 2023, 29(20): 4088-4097. DOI: 10.1158/1078-0432.CCR-22-2592.
[40]
Wang K, Xiang YJ, Yu HM, et al. Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: a preliminary multicenter single-arm prospective study[J]. Front Immunol, 2023, 14: 1107542. DOI: 10.3389/fimmu.2023.1107542.
[41]
Li G, Zhao Y, Li K, et al. Effectiveness and safety of the PD-1 inhibitor lenvatinib plus radiotherapy in patients with HCC with main PVTT: real-world data from a tertiary centre[J]. J Hepatocell Carcinoma, 2023, 10: 2037-2048. DOI: 10.2147/JHC.S432542.
[42]
Zhao Q, Zhu K, Yue J, et al. Comparison of intra-arterial chemoembolization with and without radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a meta-analysis[J]. Ther Clin Risk Manag, 2016, 13: 21-31. DOI: 10.2147/TCRM.S126181.
[43]
Jia Z, Jiang G, Tian F, et al. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis[J]. Saudi J Gastroenterol, 2016, 22(5): 353-359. DOI: 10.4103/1319-3767.191139.
[44]
Oliveira Ribeiro MC, Moda KA, Alvarez M, et al. Objective tumor response of hepatocellular carcinoma obtained by transarterial radioembolization with iodine-131-lipiodol versus transarterial chemoembolization for patients with and without portal venous thrombosis: a controlled interventional trial[J]. Acad Radiol, 2024, 31(5): 1839-1848. DOI: 10.1016/j.acra.2023.10.029.
[45]
Zeng H, Zhou C, Chen X, et al. Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis[J]. Clin Exp Med, 2023, 23(6): 2141-2150. DOI: 10.1007/s10238-023-00997-3.
[46]
Yu S, Yu M, Keane B, et al. A pilot study of pembrolizumab in combination with Y90 radioembolization in subjects with poor prognosis hepatocellular carcinoma[J]. Oncologist, 2024, 29(3): 270-e413. DOI: 10.1093/oncolo/oyad331.
[47]
Qiu Z, Yu C, Qiu X, et al. Safety and efficacy of CT-guided iodine-125 brachytherapy for portal vein tumor thrombus in hepatocellular carcinoma[J]. Acad Radiol, 2023, 30(Suppl 1): S53-S60. DOI: 10.1016/j.acra.2023.02.006.
[48]
Sui WF, Li JY, Fu JH. Transarterial chemoembolization plus stent placement for hepatocellular carcinoma with main portal vein tumor thrombosis: a meta-analysis[J]. World J Clin Oncol, 2024, 15(3): 447-455. DOI: 10.5306/wjco.v15.i3.447.
[49]
Meng P, Ma JP, Huang XF, et al. Application of radioactive iodine-125 microparticles in hepatocellular carcinoma with portal vein embolus[J]. World J Gastrointest Surg, 2024, 16(7): 2023-2030. DOI: 10.4240/wjgs.v16.i7.2023.
[50]
Lin LW, Yan LY, Ke K, et al. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis[J]. Brachytherapy, 2023, 22(6): 858-871. DOI: 10.1016/j.brachy.2023.06.229.
[51]
Li L, Cheng N, Huang X, et al. Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type Ⅲ or Ⅳ portal vein tumor thrombosis[J]. World J Surg Oncol, 2022, 20(1): 30. DOI: 10.1186/s12957-022-02495-4.
[52]
Huang J, Cai M, Huang W, et al. Transarterial chemoembolization combined with sorafenib and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study[J]. Chin Med J, 2022, 135(1): 113-115. DOI: 10.1097/CM9.0000000000001537.
[53]
Tan Z, Lu J, Zhu G, et al. Portal vein irradiation stent plus chemoembolization versus external radiotherapy plus chemoembolization in hepatocellular carcinoma with portal vein tumour thrombus: a retrospective study[J]. Cardiovasc Intervent Radiol, 2021, 44(9): 1414-1422. DOI: 10.1007/s00270-021-02889-z.
[1] 欧阳凯彤, 李静远, 杜宇. 鼻咽癌放疗前的口腔准备[J/OL]. 中华口腔医学研究杂志(电子版), 2025, 19(03): 145-152.
[2] 邱益霖, 何坤. 肝细胞癌合并门静脉癌栓的治疗进展[J/OL]. 中华普通外科学文献(电子版), 2025, 19(03): 197-202.
[3] 卢超, 陈波, 邢志祥, 周鹏, 王帅. 不同入路下腹腔镜解剖性肝脏切除术治疗肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(03): 254-257.
[4] 徐燕楠, 胡成宇, 花荣. 围手术期放射治疗在可切除腹膜后肉瘤治疗中的价值[J/OL]. 中华疝和腹壁外科杂志(电子版), 2025, 19(04): 377-382.
[5] 王楚斯, 刘家伟, 卢逸, 汤照峰. ICG荧光显影在腹腔镜肝癌切除术中临床应用[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(04): 549-553.
[6] 匡嘉文, 陈铁军, 龚远锋, 唐辉, 唐云强. TACE-HAIC联合仑伐替尼和PD-1抑制剂四联治疗Ⅲa期肝癌的疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(04): 554-560.
[7] 吴添庆, 郑梽楷, 贺珉睿, 潘扬勋, 王骏成, 陈锦滨, 周仲国. 华蟾素治疗肝癌肝动脉灌注化疗术后疼痛的疗效和安全性[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(04): 569-575.
[8] 张宏伟, 邢玉雪, 贾哲, 赫嵘, 张珂, 蒋力. 术前输注血小板在肝癌合并肝硬化门静脉高压症肝脾联合切除患者中的疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(04): 576-581.
[9] 刘晓萍, 汪嵘嵘, 吴佳慧, 吴紫云, 周伯宣. 多组学分析HAPLN1与肝癌预后及免疫细胞浸润关系[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(04): 609-618.
[10] 郭勇, 贾思颖, 高士杰, 涂康生. RNFT2在肝细胞癌中表达及其对细胞增殖、侵袭和患者预后影响[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(04): 619-627.
[11] 陈佩玥, 董芸, 邓大炜, 龚财芳, 赵俊宇, 游川. 肝癌围手术期营养风险筛查和肠内营养支持研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(04): 631-635.
[12] 杨钰泽, 徐家豪, 杨一石, 王明达, 杨田. 肝细胞癌新辅助治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(04): 515-521.
[13] 罗臻, 韦鹏程, 孙馨, 李照. 肝细胞癌骨转移研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(04): 522-527.
[14] 龚财芳, 姚娟, 李欢, 熊永福, 赵俊宇, 游川. 肝癌肝切除术后胃肠功能障碍的诊治和防治进展[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(04): 640-645.
[15] 龙吟, 何晓东, 廖建国, 黄珏, 张磊. 高复发风险肝癌患者术后靶向免疫治疗的安全性及疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(03): 379-386.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？